

IN THE CLAIMS:

Please ~~cancel~~ claim 17.

Please **add** the following new claims:

19. (New) An isolated protein comprising a full-length amino acid sequence of SEQ ID NO:2.

20. (New) An isolated protein having at least 90% sequence identity to SEQ ID NO:2, which protein, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin.

C1
21. (New) An isolated peptide comprising at least 10 amino acids, which peptide has at least 90% sequence identity to a sequence of at least 10 contiguous amino acids of mesothelin (SEQ ID NO:2), which peptide, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin.

22. (New) An isolated peptide of claim 21, which peptide comprises 10 or more contiguous peptides of SEQ ID NO:2.

23. (New) A composition comprising a protein with at least 90% sequence identity to mesothelin (SEQ ID NO:2), and a pharmaceutically acceptable carrier.

24. (New) A composition of claim 23, further comprising an adjuvant.

25. (New) A composition of claim 23, wherein said protein is conjugated to a carrier.

26. (New) A composition of claim 23, wherein the protein has the sequence of SEQ ID NO:2.

27. (New) A composition comprising a peptide comprising at least 10 contiguous amino acids of mesothelin (SEQ ID NO:2, which peptide, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin.

C1
28. (New) A composition of claim 27, further comprising an adjuvant.

29. (New) A composition of claim 27, wherein said peptide is conjugated to a carrier.

30. (New) A composition comprising a peptide of at least 10 amino acids, which peptide has at least at least 90% sequence identity to a sequence of at least 10 contiguous amino acids of mesothelin (SEQ ID NO:2), wherein said peptide, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin.

31. (New) A composition of claim 30, further comprising an adjuvant.

32. (New) A composition of claim 30, wherein said mesothelin-derived peptide is conjugated to a carrier.
